Subtopic Deep Dive
Toxic Epidermal Necrolysis and Stevens-Johnson Syndrome Classification
Research Guide
What is Toxic Epidermal Necrolysis and Stevens-Johnson Syndrome Classification?
Toxic Epidermal Necrolysis (TEN) and Stevens-Johnson Syndrome (SJS) classification involves clinical scoring systems like SCORTEN, histopathological features, and prognostic factors to distinguish these severe cutaneous adverse drug reactions.
TEN and SJS form a spectrum of epidermal necrolysis with body surface area detachment defining overlap: SJS <10%, overlap 10-30%, TEN >30%. SCORTEN predicts mortality using age, heart rate, urea, glucose, bicarbonate, malignancy, and BSA. Over 10 key papers exist, including Harr & French (2010, 666 citations) on clinical features and Guégan et al. (2005, 244 citations) on SCORTEN performance.
Why It Matters
Accurate TEN/SJS classification using SCORTEN guides ICU management and predicts mortality up to 90% in TEN (Harr & French, 2010). It informs treatment choices like cyclosporine, which reduced progression in Valeyrie-Allanore et al. (2010, 267 citations), versus IVIG, which showed no benefit in Bachot et al. (2003, 381 citations). Standardized diagnosis improves outcomes in drug-induced SCARs affecting 1-2 per million annually, aiding pharmacovigilance and trial design (Hsu et al., 2016, 347 citations).
Key Research Challenges
SCORTEN Prognostic Accuracy
SCORTEN predicts mortality but performs variably in early hospitalization days. Guégan et al. (2005, 244 citations) showed reliable predictions after day 5, yet early scores miss dynamic changes. Integrating real-time biomarkers remains unresolved.
Treatment Efficacy Variability
Immunomodulators like IVIG fail routine use per Bachot et al. (2003, 381 citations), while cyclosporine succeeds in Valeyrie-Allanore et al. (2010). Meta-analyses by Zimmermann et al. (2017, 311 citations) highlight glucocorticoids and cyclosporine promise but demand prospective trials. Overlap with DRESS complicates choices (Kardaun et al., null, 1446 citations).
SJS/TEN Spectrum Differentiation
Distinguishing SJS, overlap, and TEN relies on BSA but histopathological overlap persists. Harr & French (2010, 666 citations) note mucous membrane involvement uniformity. Epidemiological patterns vary by drug and genetics, per Hsu et al. (2016, 347 citations).
Essential Papers
Overlapping DRESS and Stevens-Johnson Syndrome: Case Report and Review of the Literature.
Sylvia H. Kardaun, Alexis Sidoroff, L. Valeyrie‐Allanore et al. · ? · PubMed · 1.4K citations
Drug-induced severe cutaneous adverse reactions (SCARs) include acute generalized exanthematous pustulosis, drug reaction with eosinophilia and systemic symptoms (DRESS), and epidermal necrolysis (...
Toxic epidermal necrolysis and Stevens-Johnson syndrome
Thomas Harr, Lars E. French · 2010 · Orphanet Journal of Rare Diseases · 666 citations
Toxic epidermal necrolysis (TEN) and Stevens Johnson Syndrome (SJS) are severe adverse cutaneous drug reactions that predominantly involve the skin and mucous membranes. Both are rare, with TEN and...
Intravenous Immunoglobulin Treatment for Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis
Nicolas Bachot, J. Revuz, Jean‐Claude Roujeau · 2003 · Archives of Dermatology · 381 citations
The confidence interval of the observed death rate excludes a dramatic decrease in mortality. No measurable effect was observed on the progression of detachment or on the speed of reepidermalizatio...
Morbidity and Mortality of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in United States Adults
Derek Y. Hsu, Joaquin C. Brieva, Nanette B. Silverberg et al. · 2016 · Journal of Investigative Dermatology · 347 citations
Current Perspectives on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis
Marianne Lerch, Carlo Mainetti, Benedetta Terziroli Beretta‐Piccoli et al. · 2017 · Clinical Reviews in Allergy & Immunology · 343 citations
Systemic Immunomodulating Therapies for Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis
Stefanie Zimmermann, Peggy Sekula, Moritz Venhoff et al. · 2017 · JAMA Dermatology · 311 citations
Although all analyses, including the unstratified model, had limitations, glucocorticosteroids and cyclosporine were the most promising systemic immunomodulating therapies for SJS/TEN. Further eval...
Open trial of ciclosporin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis
L. Valeyrie‐Allanore, P. Wolkenstein, Laurent Brochard et al. · 2010 · British Journal of Dermatology · 267 citations
Background Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN)are acute mucocutaneous reactions associated with poor prognosis. The treatment is mainly symptomatic, based on support...
Reading Guide
Foundational Papers
Start with Harr & French (2010, 666 citations) for SJS/TEN spectrum definition, then Guégan et al. (2005, 244 citations) for SCORTEN validation, and Bachot et al. (2003, 381 citations) for IVIG evidence baseline.
Recent Advances
Study Zimmermann et al. (2017, 311 citations) meta-analysis on immunomodulators and Wang et al. (2018, 265 citations) RCT on TNF-α antagonists for therapy advances.
Core Methods
SCORTEN scoring (seven variables), BSA detachment measurement, histopathological full-thickness necrosis assessment, and immunomodulator trials like cyclosporine pulse.
How PapersFlow Helps You Research Toxic Epidermal Necrolysis and Stevens-Johnson Syndrome Classification
Discover & Search
Research Agent uses searchPapers for 'SCORTEN performance in TEN' retrieving Guégan et al. (2005), then citationGraph maps 244 citing works and findSimilarPapers uncovers Zimmermann et al. (2017) meta-analysis. exaSearch scans 250M+ OpenAlex papers for histopathological classifiers beyond listed foundational studies.
Analyze & Verify
Analysis Agent applies readPaperContent to parse Bachot et al. (2003) IVIG trial data, verifyResponse with CoVe checks mortality claims against Hsu et al. (2016), and runPythonAnalysis computes SCORTEN meta-mortality via pandas on extracted scores from Guégan et al. (2005). GRADE grading scores IVIG evidence as low due to confidence intervals excluding benefit.
Synthesize & Write
Synthesis Agent detects gaps like missing etanercept RCTs post-Wang et al. (2018), flags IVIG contradictions between Bachot (2003) and others, and uses exportMermaid for SCORTEN factor flowcharts. Writing Agent employs latexEditText for case reports, latexSyncCitations integrating Valeyrie-Allanore (2010), and latexCompile for ICU protocol manuscripts.
Use Cases
"Run meta-analysis on SCORTEN mortality prediction from SJS/TEN papers."
Research Agent → searchPapers + citationGraph → Analysis Agent → runPythonAnalysis (pandas survival curves on 10 papers) → GRADE report with 95% CI verification.
"Write LaTeX review on cyclosporine vs IVIG for TEN classification."
Synthesis Agent → gap detection (Valeyrie-Allanore 2010 vs Bachot 2003) → Writing Agent → latexEditText + latexSyncCitations + latexCompile → formatted PDF with bibliography.
"Find code for SJS histopathological image classifiers from papers."
Research Agent → paperExtractUrls on Harr & French (2010) → Code Discovery → paperFindGithubRepo → githubRepoInspect → runnable Jupyter notebook for BSA scoring.
Automated Workflows
Deep Research workflow scans 50+ SCAR papers via searchPapers → citationGraph → structured report ranking SCORTEN updates. DeepScan's 7-step chain verifies treatment claims: readPaperContent on Zimmermann (2017) → CoVe → runPythonAnalysis odds ratios. Theorizer generates hypotheses on TNF-α blockade from Wang et al. (2018) linked to genetic classifiers.
Frequently Asked Questions
What defines SJS/TEN classification?
Classification uses detached epidermis: SJS <10% BSA, overlap 10-30%, TEN >30% (Harr & French, 2010). SCORTEN scores seven factors for prognosis.
What are main classification methods?
Clinical BSA measurement and SCORTEN (age, comorbidities, labs) are standard. Histopathology shows full-thickness necrosis but limited specificity (Guégan et al., 2005).
What are key papers?
Harr & French (2010, 666 citations) reviews epidemiology; Valeyrie-Allanore et al. (2010, 267 citations) validates cyclosporine; Bachot et al. (2003, 381 citations) debunks IVIG.
What open problems exist?
Early SCORTEN inaccuracy, treatment consensus lacking prospective RCTs, and genetic predictors for drug-specific risk (Zimmermann et al., 2017).
Research Drug-Induced Adverse Reactions with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Toxic Epidermal Necrolysis and Stevens-Johnson Syndrome Classification with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers
Part of the Drug-Induced Adverse Reactions Research Guide